Results 111 to 120 of about 277,626 (392)

TGF expression and macrophage accumulation in atherosclerotic renal artery stenosis.

American Society of Nephrology. Clinical Journal, 2013
BACKGROUND AND OBJECTIVES Atherosclerotic renal artery stenosis (ARAS) reduces renal blood flow and is a potential cause of chronic kidney injury, yet little is known regarding inflammatory pathways in this disorder in human participants.
M. Gloviczki, M. Keddis, V. Garovic, Hannah Friedman, S. Herrmann, M. Mckusick, S. Misra, J. Grande, L. Lerman, S. Textor   +9 more
semanticscholar   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Atherosclerotic renal artery stenosis [PDF]

Annals of Translational Medicine, 2017
Atherosclerotic renal artery stenosis (RAS) is a secondary cause of hypertension (1). RAS causes renal ischemia which leads to renin release from the juxtaglomerular cells of the kidneys (2). Renin release activates conversion of angiotensin I to angiotensin II and increases adrenal gland release of aldosterone (3).
openaire   +3 more sources

Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report [PDF]

, 2017
The treatment with fondaparinux is the effective and safe anticoagulant therapy in liver transplant patient on immunosuppressive therapy with arterial thrombosis, and it seems able to reduce liver fibrosis.
Cafolla, Arturo, Gentile, Giuseppe
core   +1 more source

Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model.

AJP - Renal Physiology, 2013
Renal artery stenosis (RAS) is an important cause of chronic renal dysfunction. Recent studies have underscored a critical role for CCL2 (MCP-1)-mediated inflammation in the progression of chronic renal damage in RAS and other chronic renal diseases.
Diping Wang, G. Warner, P. Yin, B. Knudsen, Jingfei Cheng, K. Butters, K. Lien, Catherine E. Gray, V. Garovic, L. Lerman, S. Textor, K. Nath, R. Simari, J. Grande   +13 more
semanticscholar   +1 more source

Diabetes does not impact the diagnostic performance of contrast-based fractional flow reserve: insights from the CONTRAST study [PDF]

, 2017
Background: Adenosine-free coronary pressure wire metrics have been proposed to test the functional significance of coronary artery lesions, but it is unexplored whether their diagnostic performance might be altered in patients with diabetes. Methods:
Adjedj, Julien, Barbato, Emanuele, Esposito, Giovanni, Fearon, William, Ferrone, Marco, Gargiulo, Giuseppe, Hennigan, Barry, Jeremias, Allen, Johnson, Nils, Matsumura, Mitsuaki, On behalf of the CONTRST Study Investigators, Stabile, Eugenio, Trimarco, Bruno, Zimmermann, Frederik   +13 more
core   +2 more sources

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Kissing stent management of stenosis of two branches of left renal artery bifurcation: a case report

Journal of Medical Case Reports, 2019
Background Secondary hypertension accounts for 5% of all cases of hypertension. Renal artery stenosis is one of the common causes of secondary hypertension.
Abdala M. Mkangala, Henry A. Mayala, Khamis H. Bakari, Xiang J. Dong   +3 more
doaj   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source